Literature DB >> 18434753

Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.

Laura G Sánchez-Lozada1, Edilia Tapia, Virgilia Soto, Carmen Avila-Casado, Martha Franco, Jerry L Wessale, Lin Zhao, Richard J Johnson.   

Abstract

BACKGROUND/AIMS: The effect of febuxostat (Fx), a non-purine and selective xanthine oxidase inhibitor, on glomerular microcirculatory changes in 5/6 nephrectomy (5/6 Nx) Wistar rats with and without oxonic acid (OA)-induced hyperuricemia was evaluated.
METHODS: Four groups were studied: 5/6 Nx+vehicle (V)+placebo (P) (n = 7); 5/6 Nx+V+Fx (n = 8); 5/6 Nx+OA+P (n = 6) and 5/6 Nx+OA+Fx (n = 10). OA (750 mg/kg/day, oral gavage) and Fx (3-4 mg/kg/day, drinking water) were administered for 4 weeks. Systolic blood pressure, proteinuria and plasma uric acid were measured at baseline and at the end of 4 weeks. Measurement of glomerular hemodynamics and evaluation of histology were performed at the end of 4 weeks.
RESULTS: 5/6 Nx+OA+P rats developed hyperuricemia, renal vasoconstriction and glomerular hypertension in association with further aggravation of afferent arteriolopathy compared to 5/6 Nx+V+P. Fx prevented hyperuricemia in 5/6 Nx+OA+Fx rats and ameliorated proteinuria, preserved renal function and prevented glomerular hypertension in both 5/6 Nx+V+Fx and 5/6 Nx+OA+Fx groups. Functional improvement was accompanied by preservation of afferent arteriolar morphology and reduced tubulointerstitial fibrosis.
CONCLUSION: Fx prevented renal injury in 5/6 Nx rats with and without coexisting hyperuricemia. Because Fx helped to preserve preglomerular vessel morphology, normal glomerular pressure was maintained even in the presence of systemic hypertension. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434753     DOI: 10.1159/000127837

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  49 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 2.  Urate reduction and renal preservation: what is the evidence?

Authors:  Nicolas Macías; Marian Goicoechea; M S García de Vinuesa; Ursula Verdalles; Jose Luño
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

3.  Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study.

Authors:  Iddo Z Ben-Dov; Jeremy D Kark
Journal:  Nephrol Dial Transplant       Date:  2011-01-10       Impact factor: 5.992

4.  A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.

Authors:  Masaki Ohya; Takashi Shigematsu
Journal:  Clin Exp Nephrol       Date:  2014-05-29       Impact factor: 2.801

5.  Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat.

Authors:  Dominik Steubl; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-25       Impact factor: 3.000

Review 6.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

7.  The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.

Authors:  Takayuki Tsuji; Kazuhisa Ohishi; Asumi Takeda; Daiki Goto; Taichi Sato; Naro Ohashi; Yoshihide Fujigaki; Akihiko Kato; Hideo Yasuda
Journal:  Clin Exp Nephrol       Date:  2018-04-26       Impact factor: 2.801

8.  Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice.

Authors:  Seiji Itano; Hiroyuki Kadoya; Minoru Satoh; Takashi Nakamura; Takayo Murase; Tamaki Sasaki; Yashpal S Kanwar; Naoki Kashihara
Journal:  Am J Physiol Renal Physiol       Date:  2020-09-21

9.  Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?

Authors:  Alessandro Doria; Monika A Niewczas; Paolo Fiorina
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

Review 10.  Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?

Authors:  Angelo L Gaffo; N Lawrence Edwards; Kenneth G Saag
Journal:  Arthritis Res Ther       Date:  2009-08-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.